Welcome to our dedicated page for Apollomics news (Ticker: APLM), a resource for investors and traders seeking the latest updates and insights on Apollomics stock.
Apollomics Inc. (Nasdaq: APLM) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative oncology therapies aimed at targeting specific molecular pathways to combat cancer. With a commitment to harnessing the immune system through combination therapies, Apollomics is at the forefront of developing treatments for difficult-to-treat and treatment-resistant cancers.
Originally known as CBT Pharmaceuticals, Apollomics operates with a clear vision of a world without cancer. The company's lead programs include vebreltinib (APL-101), a selective c-Met inhibitor intended for the treatment of non-small cell lung cancer (NSCLC) and other advanced tumors with c-Met alterations, and uproleselan (APL-106), an E-Selectin antagonist designed to be used adjunctively with standard chemotherapy for acute myeloid leukemia (AML).
Apollomics' commitment to rigorous scientific research is evident in their broad pipeline, consisting of nine drug candidates across multiple programs, six of which are currently in clinical stages of development. The company has built strong partnerships and in-licensed assets to advance both preclinical and clinical development programs. These partnerships play a crucial role in enhancing Apollomics' pipeline and expanding the patient populations served.
Recent milestones include:
- Presentation of interim data from the Phase 2 KUNPENG and SPARTA trials, highlighting the efficacy of vebreltinib in NSCLC patients with MetExon14 skipping mutations.
- Completion of patient enrollment in the Phase 3 bridging study of uproleselan in China, targeting relapsed or refractory AML.
- Conditional approval from the National Medical Products Administration (NMPA) of China for vebreltinib, making it the first c-Met inhibitor approved for CNS tumors with c-Met alterations.
As the company continues to advance its clinical trials and expand its therapeutic potential globally, Apollomics remains focused on providing transformative treatments that significantly improve patient outcomes.
Rhea-AI Summary
Apollomics Inc. received a notification from Nasdaq stating that the company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share. The company has 180 days to regain compliance, with the possibility of an additional 180-day period if needed. Failure to regain compliance may lead to delisting from the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
-
Rhea-AI Summary
Apollomics Inc. announced that its Chairman and CEO, Guo-Liang Yu, and President, Sanjeev Redkar, will participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference. The event will take place on January 18, 2024, at 11:00 a.m. ET. The live webcast will be accessible through B. Riley Securities, and an archived replay will be available on the Apollomics website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
-
Rhea-AI Summary
Apollomics Inc. (Nasdaq: APLM) completes enrollment in Phase 3 bridging study for uproleselan in relapsed or refractory acute myeloid leukemia patients in China
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
Rhea-AI Summary
Apollomics Inc. (APL) announced that Sanjeev Redkar, Ph.D., Co-Founder and President, will present at the 2024 Biotech Showcase on January 8, 2024, to discuss the development of medicines for difficult-to-treat cancers. The presentation will be available via webcast and archived replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
-
Rhea-AI Summary
Apollomics Inc. (Nasdaq: APLM) announced the presentation of vebreltinib efficacy and safety data from the ongoing multi-cohort Phase 2 KUNPENG trial (NCT04258033) and the ongoing global multi-cohort Phase 2 SPARTA trial (NCT03175224) at the 2023 IASLC North America Conference on Lung Cancer (NACLC). Vebreltinib appears efficacious in non-small cell lung cancer (NSCLC) patients with MetExon14 skipping mutation with or without co-occurring MET amplification. The preliminary data from NSCLC patients with MetExon14 skipping mutation from the KUNPENG and SPARTA trials showed the following efficacy and safety results: ORR in patients without co-occurring MET amplification (gene copy number<4, n=76) was 64.5%, with median DOR of 15.9 months and Disease Control Rate (DCR) of 88%. ORR in patients with MET amplification (GCN≥4, n=7) was 85.7%, with DCR of 100%. mDOR was not reached. Treatment-related adverse events of grade 3 or higher were reported in 42.2% of patients, with the most common being edema (13.3%) and ALT increase (7.2%).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.16%
Tags
-
Rhea-AI Summary
Apollomics Inc. (APL) to participate in Fireside Chat at H.C. Wainwright 4th Annual Precision Oncology Virtual Conference. Co-Founders Dr. Guo-Liang Yu and Dr. Sanjeev Redkar will discuss the company's oncology drug candidates for difficult-to-treat cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
Rhea-AI Summary
Apollomics Inc. (APLM) presents clinical results for vebreltinib in the treatment of NSCLC with MET exon 14 skipping mutation at 2023 NACLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary
Apollomics Inc. (Nasdaq: APLM) announces that its partner in China, Avistone Biotechnology Co. Ltd., has received conditional approval from the National Medical Products Administration (NMPA) of China for the commercialization of vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC). Vebreltinib, a potent c-Met inhibitor, offers a potential breakthrough for patients with MET exon 14 skipping NSCLC and other cancers driven by c-Met alterations. The approval is based on compelling clinical data and supports continued development of vebreltinib for the rest of the world. NSCLC accounts for approximately 85% of all lung cancer cases and remains a leading cause of cancer-related deaths worldwide, making this approval a significant achievement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
-
Rhea-AI Summary
Apollomics Inc. announced the addition of two new cohorts in its Phase 2 SPARTA study, evaluating vebreltinib in patients with non-small cell lung cancer and other solid tumors. The first cohort will evaluate vebreltinib in combination with osimertinib for patients with EGFR-mutated NSCLC, while the second cohort will evaluate vebreltinib monotherapy in solid tumors with high expression of c-MET and HGF. The company aims to address treatment resistance resulting from dysregulations in the HGF/c-MET axis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
Rhea-AI Summary
Apollomics Inc. announces positive clinical results for vebreltinib in treating GBM with PTPRZ-MET fusion at ESMO 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.23%
Tags
FAQ
What is the current stock price of Apollomics (APLM)?
The current stock price of Apollomics (APLM) is $9.75 as of December 20, 2024.
What is the market cap of Apollomics (APLM)?
The market cap of Apollomics (APLM) is approximately 9.4M.
What does Apollomics Inc. do?
Apollomics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative oncology therapies, particularly those involving combination treatments to harness the immune system and target specific molecular pathways to fight cancer.
What are Apollomics' lead programs?
Apollomics' lead programs include vebreltinib (APL-101), a c-Met inhibitor for treating non-small cell lung cancer and other advanced tumors, and uproleselan (APL-106), an E-Selectin antagonist used adjunctively with standard chemotherapy for acute myeloid leukemia.
What recent achievements has Apollomics made?
Recent achievements include the presentation of interim data from Phase 2 trials for vebreltinib, completion of patient enrollment in a Phase 3 study for uproleselan, and conditional approval of vebreltinib in China for CNS tumors with c-Met alterations.
How many drug candidates does Apollomics have in its pipeline?
Apollomics currently has a pipeline of nine drug candidates spread across multiple programs, with six candidates in the clinical stage of development.
What is the significance of Apollomics' partnerships?
Apollomics has built strong collaborations and in-licensed assets from various partners, enhancing its development programs and expanding the patient populations served. These partnerships are crucial for advancing their preclinical and clinical development programs.
How does vebreltinib work?
Vebreltinib is a selective c-Met inhibitor that works by inhibiting the aberrant activation of the HGF/c-MET axis, a key pathway involved in tumor growth and resistance to certain targeted therapies.
What is uproleselan used for?
Uproleselan is an E-Selectin antagonist designed to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia, potentially improving patient outcomes in combination with existing treatments.
What are the key focuses of Apollomics' current research?
Apollomics is focused on advancing clinical trials for their lead programs, vebreltinib and uproleselan, and exploring the potential of these treatments in a variety of tumor types through both monotherapy and combination therapy approaches.
What is the significance of Apollomics' recent conditional approval in China?
The conditional approval of vebreltinib by the NMPA of China for CNS tumors with c-Met alterations highlights the drug's potential to address unmet medical needs in oncology, particularly in treating aggressive brain tumors with specific genetic profiles.
How does Apollomics plan to continue its growth and advancements in oncology treatments?
Apollomics plans to continue its growth by advancing its clinical trials, strengthening partnerships, and exploring new therapeutic areas and combinations to provide transformative treatments for cancer patients globally.
Apollomics Inc.